

Add to Cart
Ursodeoxycholic Acid
Product Name | Ursodeoxycholic Acid |
Alias | 3,7-Dihydroxycholan-24-oic acid; 3alpha,7beta-Dihydroxy-6beta-cholan-24-oic acid |
CAS Registry Number | 128-13-2 |
Einecs No | 204-879-3 |
Molecular Formula | C24H39O4 |
Molecular Weight | 391.5646 |
Melt Point | 203-206℃ |
Boiling Piont | 547.148℃ at 760 mmHg |
Flash Point | 298.768℃ |
Water Soluble | practically insoluble |
Vapor Pressure | 0mmHg at 25°C |
Appearance | white powder |
Grade | Pharmaceutical Grade |
pharmchem@yccreate.com | |
Skype | lj1187668481 |
1.Role: long-term use of this drug can increase the secretion of
bile acid, and the change of bile composition, reduce the
cholesterol in bile and cholesterol ester, is conducive to the
cholesterol gallstones gradually dissolve, should not be used for
surgical treatment of cholesterol stone.
2.①Cholagogic: every time 50 mg, 150 mg per day.
② Dissolve gallstones: 450 ~ 600 mg daily (8 ~ 10 mg/kg), points 2
times in the morning and evening.After the gallstone removal, oral
50 mg per night, in order to prevent recurrence.
③Hepatomegaly, chronic hepatitis: 8 ~ 13 mg/kg per day, treatment
for 6 ~ 24 months.
④ Bile reflux gastritis: 1000 mg per day, 2 times.
3.Adverse reactions: ①The gastrointestinal tract mainly diarrhea,
incidence of about 2%.Occasional constipation, stomach pain,
pancreatitis, etc.
② The hepatotoxicity of liver toxicity is not obvious.
③The respiratory system data reported abroad, can appear
bronchitis, cough, pharyngitis and other respiratory adverse
④The central nervous system Occasional headache, dizziness, etc.
⑤ Skin can appear itching, hair loss, etc.
⑥6. Musculoskeletal There will be joint pain, arthritis, back pain
and muscle pain, etc.
⑦Carcinogenic and mutagenic effects Animal studies did not find
this drug and mutation, microscope, found no liver cells incubated
with this drug there are changes in the structure.Experiments on
animals (mice and rats)
4.Note: 1. The contraindications to (1) the severe liver function
impairment.Biliary tract (2) is completely blocked.(3) allergic to
bile acid (foreign).
2. Careful Pregnant women and nursing mothers.
3. The influence of drugs for children The efficacy and safety of
children to use this drug is not yet clear, not approved for
children abroad.
4. The influence of drugs on pregnancy The FDA this drug is divided
into pregnancy risk level for class B.
5. The influence of drugs on inspection value or diagnosis
Cholelith disease patients using this drug, blood fat no special
change, long-term use of this drug can increase the number of
peripheral blood platelet.
6. Before and after medication and drug should check or monitoring
(1) should be at the beginning of treatment, 1 month and 3 months
after treatment to check liver enzyme indicators (including alanine
aminotransferase and aspartate aminotransferase), after review once
every six months.
(2) treatment 1 years should do 1 B ultrasonic examination every
six months.
(3) the primary biliary cirrhosis also should pay attention to the
total bilirubin, alkaline phosphatase and immunoglobulin IgM
monitoring.